top of page

Virginia Urology is the First Independent Urology Practice in the US to Scan Patients with POSLUMA®




MECHANICSVILLE, VA –– Virginia Urology is the first independent practice in the US and the first Large Urology Group Practice Association (LUGPA) provider in the US to scan patients with POSLUMA®. "Virginia Urology is proud to be a pioneer in advanced prostate cancer imaging by offering our patients the latest in both diagnostic and therapeutic options. We are thrilled to be able to add the latest PSMA imaging agent, POSLUMA®, to our comprehensive cancer services," stated Brigette Booth, CEO of Virginia Urology.


POSLUMA was developed by Blue Earth Diagnostics and distributed by PETNET Solutions Inc, a Siemens Healthineers Company. According to Blue Earth Diagnostics, POSLUMA is a "Prostate-Specific Membrane Antigen (PSMA)-targeted PET diagnostic imaging agent indicated for use in men with prostate cancer with PSMA positive lesions with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.1 For these men, a POSLUMA PET scan can help determine if prostate cancer is present or has spread within the prostate or prostate bed or to other parts of the body."


A POSLUMA scan uses a PET/CT scanner and typically takes 20 to 30 minutes. PET imaging is usually combined at the same time with computerized tomography (CT) scanning to improve the quality of the images and to help localize abnormalities. Like many diagnostic imaging agents, POSLUMA includes a radioactive element (fluorine-18) used to produce images of the body and its internal organs and tissues.


Other than skin cancer, prostate cancer is the most common cancer in American men. Determining the extent of primary prostate cancer and whether it may have spread is important. Most primary prostate cancer can be successfully treated. Still, up to 25% of men with primary prostate cancer may have detectable lymph node metastases, which are associated with a risk for recurrence and decreased overall survival. Knowing the location of the disease or where it may have spread is essential to making appropriate patient management decisions.


PSMA PET/CT has impacted the diagnosis and treatment planning for patients with Prostate Cancer. Adding POSLUMA to our service in Richmond, VA, will only enhance the level of care. Captive Radiology is proud to play a role in delivering this technology to Virginia Urology, its physicians, and, most importantly, the men being cared for. Congratulations to the teams at Blue Earth Diagnostics, PETNET Solutions, and Virginia Urology for being on the cutting edge of Prostate Cancer care.



100 views0 comments

コメント


bottom of page